Effects of eldecalcitol and ibandronate on secondary osteoporosis and muscle wasting in rats with adjuvant-induced arthritis

Yuichi Ono, Naohisa Miyakoshi*, Yuji Kasukawa, Hiroyuki Nagasawa, Hiroyuki Tsuchie, Manabu Akagawa, Itsuki Nagahata, Yusuke Yuasa, Chiaki Sato, Yoichi Shimada

Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan

ABSTRACT

Objectives: Rheumatoid arthritis (RA) is characterized by chronic inflammation of the synovium, progressive erosion of the articular cartilage, and joint destruction. RA also causes secondary osteoporosis and muscle wasting. We investigated the effects of ibandronate (IBN), a bisphosphonate; eldecalcitol (ELD), an active vitamin D3 derivative; and combination treatment with both agents on secondary osteoporosis and muscle wasting using adjuvant-induced arthritis rats.

Methods: Arthritis was induced in 8-week-old male Lewis rats. Rats were randomized into 4 treatment groups and an untreated normal control group: IBN (subcutaneously, once every 2 weeks, 10 mg/kg), ELD (orally, once daily, 30 ng/kg/day), IBN + ELD, vehicle, and control. Paw thickness measurements were performed for evaluation of arthritis. The femur was scanned using dual-energy X-ray absorptiometry. Cross-sectional areas of left tibialis and anterior muscle fibers and the expression of MuRF1, atrogin-1, MyoD, and myogenin in the gastrocnemius muscle were measured to evaluate muscle wasting.

Results: IBN and/or ELD increased bone mineral density (BMD) in the femur. In addition, there was an additive effect of combination treatment compared with single treatments for BMD. However, IBN and/or ELD did not inhibit muscle wasting in adjuvant-induced arthritis rats.

Conclusions: Combination treatment with IBN and ELD may be effective for secondary osteoporosis associated with RA. Other treatments are necessary for muscle wasting associated with RA. Studies in humans are needed to confirm these findings.

© 2018 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease characterized by proliferative and invasive synovitis; it results in destruction of joints and erosion of cartilage and bone [1]. In addition, it has been reported that RA is often associated with periarticular or generalized osteoporosis [2,3], decreased muscle function, and low muscle mass [4,5]. Patients with RA frequently have pain and impaired muscle function, which limits physical activity and decreases quality of life [6–8]. Therefore, it is important to prevent physical destruction of joints, bone, and muscle in patients with RA.

Biologics are commonly used to treat RA. However, the effects of biologics on bone mineral density (BMD) and muscle atrophy in patients with RA are still unclear. Additional treatments for preventing or recovering bone or muscle in patients with RA are required. Bisphosphonates and active vitamin D are widely used in the treatment of secondary osteoporosis associated with RA [9]. Bisphosphonates have a high affinity for bone tissue and are incorporated into osteoclasts during bone resorption [10]; they also induce apoptosis [11]. Ibandronate (IBN), a nitrogen-containing bisphosphonate, is effective in preventing bone fragility fractures in patients with osteoporosis [12]. IBN was shown to increase lumbar and total body BMD to a greater extent than did alendronate or risedronate, which are widely used in the treatment of osteoporosis [13]. Although it has been reported that IBN suppresses muscle atrophy in animal experiments of RA [14], its effects on bone and muscle have not been completely clarified.

Vitamin D is necessary for bone health because of its role in the regulation of calcium homeostasis, and vitamin D serum levels influence an adequate response to bisphosphonate treatment [15].
In addition, it was reported that vitamin D deficiency was common in RA patients [16]. Thus, vitamin D is important in treating secondary osteoporosis with RA. Eldecalcitol (ELD) is an active vitamin D3 derivative used for the treatment of osteoporosis in Japan [17]. It is frequently used in combination with other antosteoporotic drugs. Sakai et al. [18] reported that treatment with the combination of IBN plus ELD was beneficial in the treatment of osteoporosis in aged postmenopausal osteopenia model rats. There are several reports of the effect of vitamin D on muscle strength and mobility in humans [19,20]. Similarly, ELD has been shown to have a positive effect on skeletal muscle in both animal and human studies [21,22]. However, the effect of ELD used as a single agent or combined with a bisphosphonate for secondary osteoporosis and muscle atrophy associated with RA is unknown.

Adjuvant-induced arthritis (AIA) is a widely used experimental animal model because it shows similarities with human RA [23,24]. After immunization, rats develop inflammation and polyarthritis that lead to decreased body weight and loss of skeletal muscle mass [25]. Muscle wasting in arthritic rats is associated with an increase in the activity of the ubiquitin-proteasome pathway, and the key enzymes in this process are two E3 ubiquitin ligases, muscle ring finger protein-1 (MuRF1) and atrogin-1 [26]. In this study, we investigated the effects of IBN, ELD, and a combination of IBN + ELD on secondary osteoporosis and muscle wasting using AIA rats.

2. Methods

2.1. Animals and experimental protocol

Eight-week-old male Lewis rats (Japan SLC, Shizuoka, Japan) were used in this study. Adjuvant arthritis was induced by subcutaneous injection of a prepared suspension of *Mycobacterium tuberculosis* H37Ra (Difco Laboratories, Detroit, MI, USA) in paraffin oil (5 mg/ml) into the footpad of the right hind paw (50 μl). Normal untreated rats were used as a control (CON) group. From day 21 after adjuvant injection, the CON and AIA rats were divided into 5 groups (n = 10 in each group): (1) CON group, normal control rats; (2) Vehicle group, AIA control rats treated with isotonized sodium chloride solution (Otsuka Pharmaceutical Factory, Tokushima, Japan) for vehicle of IBN and medium-chain triglyceride (The Nisshin Oillio Group, Tokyo, Japan) for vehicle of ELD; (3) IBN group, AIA rats treated with IBN (subcutaneously, once every 2 weeks, 10 μg/kg) (Bovivita, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan); (4) ELD group, AIA rats treated with ELD (orally, once daily, 30 ng/kg/day) (Chugai Pharmaceutical Co., Ltd.); and (5) IBN + ELD group, AIA rats treated with a combination of IBN and ELD. The dose of IBN or ELD was based on previous studies [18,27], in which IBN and ELD elevated femoral and lumbar spinal BMD in ovariectomized rats. Rats were allowed ad libitum access to tap water and commercial standard rodent chow (CE-7; Clea Japan, Tokyo, Japan). Total RNA was collected from tissue using TRIzol manufacturer’s protocol. The total RNA was determined using NanoDrop spectrophotometer ND-1000 (Thermo Fisher Scientific, Waltham, MA, USA).

2.2. Tissue preparation

Left femurs were harvested and used for measurement of BMD by dual-energy X-ray absorptiometry (DXA). Left tibialis anterior (TA) muscles were harvested and stored in liquid nitrogen for measurement of cross-sectional areas (CSAs), and left gastrocnemius muscles were harvested and stored in RNAlater solution (Qiagen, Hilden, Germany) at −80 °C for real-time polymerase chain reaction (PCR).

The Animal Research Committee of our institute approved the protocol for all animal experiments, and all animal experiments adhered to the “Guidelines for Animal Experimentation” of the university.

2.3. Body weight

Body weight was measured at the beginning and end of the experiment (Keimaiko; Yamato-scale, Hyogo, Japan).

2.4. Clinical measurements of arthritis by paw thickness

Clinical signs of arthritis in each hind paw were assessed once weekly by investigators blind to the treatment group, as previously described [28,29]. Hind footpad width was also measured once weekly with calipers (Dial Thickness Gauge; Ozaki Mfg. Co., Ltd., Tokyo, Japan) [30].

2.5. BMD measurement

BMD of the total femur was measured using DXA (QDR-4500 Delphi; Hologic, Bedford, MA, USA). Results were used to assess secondary osteoporosis.

2.6. Histological analysis of muscle

Left TA muscles in rats in the 5 groups that were treated for 4 weeks (n = 5) were analyzed histologically. Samples were cut into 10-μm thick transverse serial sections at the thickest part of the muscle belly, with the cryostat maintained at −18 °C. Sections were stained histochemically with hematoxylin and eosin. To measure CSAs of muscle fibers, microscopic images at a magnification of 200× were captured digitally (FACEScope IHP520; Alfabio, Gunma, Japan), and individual muscle fibers were traced on-screen using ImageJ image analysis software (National Institutes of Health, Bethesda, MD, USA). Areas were calculated using ImageJ software based on a calibrated pixel-to-actual size (micrometer) ratio. Fifty fibers per muscle were randomly chosen, muscle fiber CSA was measured, and mean CSA for one muscle fiber was calculated. With this method, intraobserver variation, as assessed by the coefficient of variation for 3 corresponding measurements in 50 randomly selected fibers, ranged from 0.1% to 1.2%. Interobserver variation between the three investigators, as assessed by the coefficient of variation of measurements in 50 randomly selected images, ranged from 3.7% to 8.5%.

2.7. Gene expression analysis of skeletal muscle

Gastrocnemius muscles were isolated from the tibias of rats from all groups treated for 2 and 4 weeks (n = 5). We evaluated the gene expression of MyoD, and myogenin as muscle anabolic markers and atrogin-1 and MuRF1 as muscle catabolic markers. Samples were crushed with a homogenizer (MS-100R; Tomy, Tokyo, Japan). Total RNA was collected from tissue using TRIzol reagent (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s protocol. The final concentration of RNA was determined with NanoDrop spectrophotometer ND-1000 (Thermo Fisher Scientific, Waltham, MA, USA).

First-strand cDNA synthesis was performed using the First-Strand cDNA Synthesis Kit (GE Healthcare, Milwaukee, WI, USA). Quantitative reverse-transcription PCR was done using Light Cycler 480 (Roche, West Sussex, United Kingdom) according to the manufacturer’s protocol, with TaqMan probes specific for rat MyoD (TaqMan probe ID: Rn01457527_g1), myogenin (TaqMan probe ID: Rn01490689_g1), atrogin-1 (TaqMan probe ID: Rn00591730_m1), and MuRF1 (TaqMan probe ID: Rn01490689_g1).
Amplification of glyceraldehyde3-phosphate dehydrogenase was used as an internal control for sample normalization (TaqMan probe ID: Rn00590197_m1).

2.8. Statistical analyses

Statistical analyses were performed using the Statistical Package for the Biosciences software ver. 9.6 (Akita University, Akita, Japan) [31]. Continuous variables were expressed as mean ± standard deviation. Differences between groups at each time point were evaluated using one-way analysis of variance (ANOVA). Multiple comparisons were made using Scheffe and Dunn post hoc tests, as appropriate. Nonparametric data, including skeletal muscle gene expression, was analyzed by Dunn method. Parametric data were analyzed by Scheffe method. Skeletal muscle gene expression was analyzed by the Wilcoxon rank-sum test based on the data of control rats at 2 weeks. Data were analyzed by 1-way ANOVA followed by a least significant difference test. Values of P < 0.05 were considered significant.

3. Results

3.1. Body weight and arthritis

The body weight of rats in the CON group was significantly higher than rats in the AIA groups (Vehicle, IBN, ELD, and IBN + ELD group) at the beginning and end of the experiment (P < 0.05). However, no significant differences in weight were seen among any of the AIA groups (Table 1).

The paw thickness of rats in the AIA groups was significantly greater than rats in the CON group at 2 weeks. Data were analyzed by Scheffe method. Skeletal muscle gene expression was analyzed by the Wilcoxon rank-sum test based on the data of control rats at 2 weeks. Data were analyzed by 1-way ANOVA followed by a least significant difference test. Values of P < 0.05 were considered significant.

3.2. Bone mineral density

At the end of 2 and 4 weeks, total femoral BMD was significantly decreased in the AIA groups (Vehicle, IBN, ELD, and IBN + ELD groups) compared with the CON group (P < 0.05). BMD of total femur compared with that of vehicle group (P < 0.05). At 4 weeks, an additional increase was observed at the total femoral BMD in the IBN + ELD group, compared with IBN alone or ELD alone groups (P < 0.05) (Table 2).

3.3. Cross-sectional area

The CSA of TA muscle fibers of rats in the CON group was significantly greater than rats in the AIA groups at the end of 2 and 4 weeks. However, no significant differences in the CSA of TA muscle fibers were seen among the AIA groups at the both of 2 and 4 weeks (Table 3).

3.4. Gene expression analysis of skeletal muscle

Two weeks of treatment with ELD alone and IBN + ELD showed significantly higher mRNA expression of MuRF1 (P < 0.05) compared with the CON group (Fig. 2B). IBN and/or ELD treatment did not affect mRNA expression of atrogin-1 at 2 or 4 weeks (Fig. 2A, C).

On the other hand, in regard to the myogenic regulatory factors, AIA rats (Vehicle group) revealed significantly higher mRNA expression levels of MyoD at 2 and 4 weeks compared with the CON group (P < 0.05) (Fig. 3A, C). Two weeks' treatment with IBN and 4 weeks' treatment with ELD showed significantly higher MyoD expression compared with the CON group (P < 0.05) (Fig. 3A, C). Myogenin mRNA expression levels in the IBN, ELD, and IBN + ELD groups at 2 weeks and IBN group at 4 weeks were significantly higher than levels in the CON group (P < 0.05) (Fig. 3B, D).

However, there were no significant differences in the muscle anabolic (MyoD and myogenin) and catabolic markers (MuRF1 and atrogin-1) among the AIA groups at both 2 and 4 weeks (Figs. 2 and 3).

4. Discussion

In the present study, we demonstrated that IBN and/or ELD increased BMD in the femur, whereas IBN and/or ELD did not inhibit muscle wasting in AIA rats.

There are several reports on combination therapy with IBN and ELD. Sakai et al. [18] reported that treatment with IBN + ELD had a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats. Takada et al. [32] reported that IBN + ELD for 6 months significantly improved bone strength of the proximal femur in postmenopausal women with osteoporosis. Bisphosphonates augment BMD through the inhibition of osteoclast activity [33]. Third-generation nitrogen-containing bisphosphonates, such as IBN, inhibit farnesyl pyrophosphate synthetase in the mevalonate pathway in osteoclasts and induce apoptosis of osteoclasts, thereby inhibiting osteoclastic activity [11]. On the other hand, it was reported that ELD increased BMD by suppressing the expression of receptor activator of nuclear factor-kappa B ligand in bone tissue, a stimulus of osteoclast differentiation and bone resorption [34]. This difference in mechanism of action on osteoclasts might be the reason for the additive effect of ELD on the increase in BMD.

AIA rats revealed significantly higher mRNA expression levels of MyoD at 2 and 4 weeks compared with the CON group. Impaired skeletal muscle regeneration affects muscle atrophy, and MyoD and myogenin are important factors in muscle regeneration. Following damage in adult skeletal muscle, satellite cells start to proliferate and differentiate, and expression of MyoD and myogenin increases [35]. Expression of MyoD is related to activation and proliferation of satellite cells, whereas myogenin reflects terminal myoblast differentiation [36]. Castillo et al. [37] reported that AIA increases the expression of MyoD and myogenin in rats. The increased expression of MyoD was considered to reflect stimulated muscle regeneration in AIA rats.

In the skeletal muscle, when muscle satellite cells differentiate and proliferate, and damaged muscles are regenerated, several myogenic regulatory factors are involved, such as MyoD and myogenin [36]. An in vitro study showed that ELD upregulated gene expression of vitamin D receptors, MyoD, insulin-like growth factor, and myosin heavy chain subtypes in differentiated C2C12
myoblasts [38]. Kinoshita et al. [21] reported that ELD treatment increased TA muscle type II fiber CSA and improved muscle strength by inducing higher expression of myogenin in the glucocorticoid-induced myopathy rat model. Based on these results, we expected that IBN and/or ELD treatment regenerated muscle atrophy in the AIA rats by stimulating the expression of myogenic regulatory factors such as myogenin and MyoD at the beginning of the experiment. However, muscle atrophy was not improved by administration of IBN and/or ELD, and there were no significant differences in the expression of anabolic skeletal muscle genes (MyoD and myogenin) among the AIA rats. This might be caused by the severe muscle atrophy in AIA rats or a lower dose and shorter duration of IBN and ELD treatment in the present study.

MuRF1 and atrogin-1 are key enzymes in the ubiquitin-proteasome proteolytic pathway [26,39]. In addition, inflammatory cytokines such as tumor necrosis factor-α and IL-6 promote NFκB signaling and induce muscle protein degradation and apoptosis [40]. Granado et al. reported that increased expression of MuRF1 and atrogin-1 was involved in muscle wasting in AIA rats [26], and Watanabe et al. reported that IBN treatment significantly inhibited skeletal muscle atrophy by suppressing the expression of atrogens (atrogin-1 and MuRF1) in denervation-induced immobilization model mice [14]. Thus, we hypothesized that IBN and/or ELD administration would suppress the expression of atrogens such as MuRF-1. However, instead, ELD and IBN + ELD stimulated the expression of MuRF-1 in AIA rats. Although there are several reports that administration of active vitamin D decreased food intake and increased expression of MuRF1 in rats [41,42], further investigation is needed regarding the effects of IBN and/or ELD on atrogens.

5. Conclusions

In conclusion, IBN and/or ELD treatment increased femoral BMD in AIA rats. However, IBN and/or ELD treatment did not inhibit muscle wasting. These results suggest that combination treatment of IBN and ELD may be effective for secondary osteoporosis associated with RA, but another treatment might be necessary for muscle wasting associated with RA. Studies in humans are needed to confirm these findings.
**Fig. 2.** Muscle catabolic markers. Measurement of Atrogin-1 (A, C) and MuRF1 (B, D) expression in gastrocnemius muscle at 2 and 4 weeks using reverse-transcription polymerase chain reaction. \(n = 5\) per group. Values are presented as mean ± standard deviation. \(*P < 0.05\) by Dunn multiple comparison test. MuRF1, muscle ring finger protein-1; CON, control; IBN, ibandronate; ELD, eldecalcitol.

**Fig. 3.** Muscle anabolic markers. Measurement of MyoD (A, C) and Myogenin (B, D) expression in gastrocnemius muscle at 2 and 4 weeks using reverse-transcription polymerase chain reaction. \(n = 5\) per group. Values are presented as mean ± standard deviation. \(*P < 0.05\) by Dunn multiple comparison test. CON, control; IBN, ibandronate; ELD, eldecalcitol.
Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

The authors are grateful for the skillful technical assistance of Ran Matsuzawa. The authors thank Chugai Pharmaceutical Co., Ltd. for providing eldecalcitol. ORCID. Yuichi Ono: https://orcid.org/0000-0001-9250-457X; Naohisa Miyakoshi: https://orcid.org/0000-0001-5175-3350; Yuji Kasukawa: https://orcid.org/0000-0001-7008-675X; Hiroyuki Nagasawa: https://orcid.org/0000-0001-7641-8188; Hiroyuki Tsuchie: https://orcid.org/0000-0001-7008-675X; Hiroyuki Nagasawa: https://orcid.org/0000-0001-5175-3350; Yuji Kasukawa: https://orcid.org/0000-0001-9250-457X; Naohisa Miyakoshi: https://orcid.org/0000-0001-7641-8188; Itsuki Nagahara: https://orcid.org/0000-0002-1699-3284; Yusuke Yuasa: https://orcid.org/0000-0002-5659-7278; Chiaki Sato: https://orcid.org/0000-0003-1449-2053; Yoichi Shimada: https://orcid.org/0000-0002-6523-3249.

References

[1] Güler–Yükcel M, Klarenbeek NB, Goekoop-Ruiterman YP, de Vries-Brouwer JK, van der Kooij SM, Gerards AH, et al. Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis. Arthritis Res Ther 2010;12:896.
[2] Hoshino K, Hanuy T, Arai K, Takahashi HE. Mineral density and histomorphometric assessment of bone changes in the proximal tibia early after induction of type II collagen-induced arthritis in growing and mature rats. J Bone Miner Metabol 2001;19:76–83.
[3] McNlnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205–19.
[4] van Bokhorst-de van der Schueren MA, Konijn NP, Bultink IE, Lems WF, Earthman CP, van Tuyl LH. Relevance of the new pre-cachexia and cachexia definitions for patients with rheumatoid arthritis. Clin Nutr 2012;31:1008–10.
[5] Elkan AC, Håkansson N, Frostegård J, Cederholm T, Hafström I. Rheumatoid cachexia is associated with dyslipidaemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2009;11:R37.
[6] Häkkinen A, Koutiainen H, Hannonen P, Ylenen J, Mäkinen H, Sokka T. Muscle strength, pain, and disease activity explain individual subdimensions of the Health Assessment Questionnaire disability index, especially in women with rheumatoid arthritis. Ann Rheum Dis 2006;65:30–4.
[7] Sokka T, Håkkinen A, Koutiainen H, Mäilefält JF, Tolosa S, Mark Hansen T, et al. Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study. Arthritis Rheum 2008;59:42–50.
[8] Plasigi G. The role of physical activity in rheumatoid arthritis. Physiol Behav 2008;94:270–5.
[9] Omata Y, Hagiwara F, Nishino J, Matsudaira K, Kadono Y, Juji T, et al. Vertebral fracture incidence adequate response to ibandronate and eldecalcitol in postmenopausal Japanese women. Bone Miner 2005;45:83–91.
[10] Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, et al. Osteoporosis: the global disease. Lancet 2004;363:1789–99.
[11] Van Eden W, Waksman BH. Immune regulation in adjuvant-induced arthritis: possible implications for innovative therapeutic strategies in arthritis. Arthritis Rheum 2003;48:1788–96.
[12] Castillaero E, Martín AL, López-Menduina M, Granado M, Villanúa MA, López-Calderón A. IgF-1 system, antibodies and myogenic regulatory factors in adjuvant-induced muscle wasting. Med Cell Endocrinol 2009;30:8–16.
[13] Granado M, Prieo T, Martín AL, Villanúa MA, López-Calderón A. Ghrelin receptor agonist GHRP-2 prevents arthritis-induced increase in E3 ubiquitin- ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscle. Am J Physiol Endocrinol Metabol 2005;289:E1007–14.
[14] Takada S, Smith SY, Tamura T, Saito H, Takahashi F, Samadaf R, et al. Long-term treatment with eldecalcitol (1α, 25-dihydroxy-2α-(3-hydroxypropyloxy) vitamin D3) suppresses bone turnover and leads to prevention of bone loss and bone fragility in ovariectomized rats. Calcif Tissue Int 2015;96:45–55.
[15] Le Goff B, Soltner E, Charrier C, Maugars Y, Rédini F, Heymann D, et al. A combination of metinolretate and zoleodronic acid prevents bone erosions and systemic bone loss in collagen induced arthritis. Arthritis Res Ther 2009;11:R185.
[16] Wu Q, Xiong Z, Zhang X, Lu J, Zhang X, Chen W, et al. Secondary osteoporosis in collagen-induced arthritis rats. J Bone Miner Metabol 2016;34:300–16.
[17] Romaña S, Simals NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, et al. Osteoporosis: the global disease. Lancet 2004;363:1789–99.
[18] Murata K, Yano E. Medical statistics for evidence-based medicine with SPBS user’s guide. Tokyo: Nankodo Publisher; 2002.
[19] Takada J, Wada H, Iba K, Sasaki K, Dohke T, Kanaya K, et al. Combined use of ibandronate and eldecalcitol in postmenopausal Japanese women with osteo- porosis. J Orthop Surg 2016;24:562–6.
[20] Humes DE, Wright KW, Greenberg AE, HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonate promotes apoptosis in murine osteoclasts in vitro and in vivo. Bone Min J Res 1995;10:1478–87.
[21] Jarada S, Mizoguchi T, Kobayashi Y, Nakamichi Y, Takada S, Sakai T, et al. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J Bone Miner Res 2012;27:461–73.
[22] Sakurai T, Kishimura O, Kano Y, Ohno H, Jr, IL, Izawa T, et al. Role of nitric oxide in muscle regeneration following eccentric muscle contractions in rat skeletal muscle. J Physiol Sci 2013;63:263–70.
[23] Tajbakhsh S. Skeletal muscle stem cells in developmental versus regenerative myogenesis. J Intern Med 2009;266:372–85.
[24] Castillaero E, Martín AL, López-Menduina M, Villanúa MA, López-Calderón A. Eicosapentaenoic acid attenuates arthritis-induced muscle wasting acting on atrogin-1 and on myogenic regulatory factors. Am J Physiol Regul Integr Comp Physiol 2009;297:R1322–31.
[25] Saito H, Kishimoto KN, Mori Y, Okuno H, Tanaka M, Ito E. A vitamin D analogue, eldecalcitol, enhances expression of fast myosin heavy chain subtypes in differentiarted C2C12 myoblasts. J Orthop Sci 2017;22:345–50.
[26] Bodine SC, Latres E, Baumberter S, Lai XW, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704–8.
[27] Sakuma Y, Yamaguchi A, Sarcopenia and age-related endocrine function. J Intern Med 2012;271:28–41.
[28] Cegla L, Rivas DA, Pojednic RM, Price LL, Harris SS, Smith D, et al. Effects of alkali supplementation and vitamin D insufficiency on rat skeletal muscle. Endocrinology 2013;44:544–64.
[29] Tričlaková K, Jaypers RT, Wijesinghe J, de Haan A, Degens H. Effects of alfalcaldol on circulating cytokines and growth factors in rat skeletal muscle. J Physiol Sci 2011;61:525–35.